DOTA-LM3
A somatostatin-receptor blocker that carries a radioactive metal to neuroendocrine tumours, for scans and for treatment
DOTA-LM3 is a small synthetic peptide that sits on somatostatin receptor 2, the receptor most neuroendocrine tumours carry, without switching it on. A DOTA ring at one end holds a radioactive metal. With gallium-68 it is a PET tracer; with lutetium-177, terbium-161 or actinium-225 it delivers radiation to the tumour. A 51-patient treatment study, two small randomised imaging studies and a run of case reports make up the human record. It is an investigational hospital radiopharmaceutical with no approval anywhere.
Used in human trials: Median 6.1 GBq (range 2.8-7.4 GBq), Per cycle, Intravenous (Lutetium-177 DOTA-LM3, metastatic neuroendocrine neoplasms (51 pati...) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Most well-differentiated neuroendocrine tumours, the slow-growing cancers that start in hormone-making cells of the gut, pancreas and lungs, carry large numbers of somatostatin receptor 2 (SSTR2). The approved tracers and the approved radioligand therapy for these tumours use agonists such as DOTATATE and DOTATOC, which activate the receptor and are pulled inside the cell. DOTA-LM3 takes the other approach. LM3 is a cyclic peptide antagonist: it binds SSTR2 without activating it and stays mostly on the cell surface. A DOTA ring at one end holds the radioactive metal.
The reason to try an antagonist is that it can find more binding sites. In the 51-patient first-in-human treatment study, lutetium-177 DOTA-LM3 stayed longer in the body and gave higher radiation doses to tumours than the agonist lutetium-177 DOTATOC measured with the same method, and it worked in some people whose tumours took up little or no agonist. The other side of that coin is that the kidneys, spleen and bone marrow also got more radiation. Low platelet counts were the main serious side effect.
For imaging, two randomised double-blind studies from Beijing gave gallium-68 DOTA-LM3 to patients with neuroendocrine tumours. It was well tolerated by most, left less tracer in normal organs than gallium-68 DOTATATE, and found more lesions with better contrast against the liver. Single case reports describe it finding a hormone-secreting tumour behind ectopic Cushing syndrome and confirming recurrent disease before treatment.
For therapy beyond lutetium-177, the work has moved to other radionuclides. Terbium-161 gives off short-range electrons as well as beta particles, and in mice and cells it was far more potent on DOTA-LM3 than lutetium-177 was; a phase 0 study in eight patients then found a median tumour dose 7.6 times that of lutetium-177 DOTATOC from a 1 GBq test injection. Actinium-225, an alpha emitter, has been given on DOTA-LM3 alone or together with lutetium-177 ('TANDEM') to 35 people whose disease progressed after standard radioligand therapy, with mostly mild early side effects but some serious late blood, kidney and liver toxicity and one case of acute myeloid leukaemia.
The evidence is early and comes from a few centres. A 2026 review in the Journal of Nuclear Medicine notes that antagonist results come mainly from small, mixed early-phase studies, that blood toxicity is higher, and that no prospective trial has yet shown that antagonists help people live longer. DOTA-LM3 is made in hospital radiopharmacies and given only in nuclear-medicine departments. It has no FDA or EMA approval and is not something anyone can buy or use at home.
Mechanism of Action
DOTA-LM3 has no drug effect of its own at the amounts given. The peptide is a carrier that finds somatostatin receptor 2, and the radioactive metal in its DOTA ring is either imaged or irradiates the cells around it.
SSTR2 antagonism
Binds somatostatin receptor 2 without activating it; on human, monkey, rat and mouse brain sections the lutetium form bound one class of high-affinity sites, while the gallium complex bound less tightly (2026 study).
Gallium-68 for PET
Tumour uptake was high within 5 minutes of injection, and normal organs took up less than with gallium-68 DOTATATE (2021 and 2022 randomised studies).
Beta, electron and alpha therapy
Lutetium-177 and terbium-161 emit beta particles, terbium-161 also short-range electrons, and actinium-225 alpha particles; on the cell membrane, where an antagonist stays, the extra electrons of terbium-161 added a further dose-response term in cells (2024 study).
Normal-organ dose
Kidneys, spleen and bone marrow received more radiation than with an agonist, which shows up as lower platelet counts in some patients (2021 study) and in mice (2024 study).
Published Research
These are the studies of DOTA-LM3 read from their PubMed abstracts on October 29, 2026: thirteen in patients (two randomised imaging studies, a 51-patient treatment study, a phase 0 dosimetry study, a 35-patient actinium-225 series and eight single-patient reports), six in cells or animals, one on human and animal tissue and one review. Four records whose titles name only the radionuclide or the receptor class are carded because their abstracts name DOTA-LM3 as the agent tested. Case reports describe what happened to one person and cannot show how often it would happen to others.
First lutetium-177 DOTA-LM3 treatment study, 51 patients
Fifty-one people with metastatic neuroendocrine neoplasms were treated between 2017 and 2019 with a median of 6.1 GBq per cycle (range 2.8 to 7.4 GBq). Of 47 assessed, 17 had a partial response and 23 stable disease by RECIST, a disease control rate of 85.1%. Grade 3 thrombocytopenia occurred in 3 patients and mild nausea in 5; kidney and liver function did not decline. Tumours and organs received higher doses than with lutetium-177 DOTATOC.
Randomised safety and dosimetry study of the gallium-68 tracer
Sixteen patients were randomised to gallium-68 DOTA-LM3 or gallium-68 NODAGA-LM3, eight per arm. The DOTA-LM3 group received about 172 MBq with 40 µg of peptide. Two of them had grade 2 nausea and one grade 1 vomiting. Tumour uptake was already high at 5 minutes and rose a little to 30 minutes, normal organs took up less than in the NODAGA arm, and the effective dose was 0.025 mSv per MBq.
Randomised diagnostic study against gallium-68 DOTATATE
Forty patients with well-differentiated neuroendocrine tumours had an LM3 scan one day and a DOTATATE scan the next. In the 20 who received gallium-68 DOTA-LM3, normal organs took up less tracer, more lesions were found, and tumour uptake was similar (median SUVmax 16.1 against 17.8) but contrast against the liver was higher (median tumour-to-liver ratio 5.2 against 2.1).
Terbium-161 DOTA-LM3: phase 0 crossover study
Eight patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumours received 1 GBq of terbium-161 DOTA-LM3 and, four weeks apart, 1 GBq of lutetium-177 DOTATOC. Median tumour dose was 36.6 Gy per GBq against 7.0, and tumour retention was longer (103 against 83 hours). Kidney and marrow doses were also higher. Grade 1 to 3 adverse events occurred in 6 of 8, none judged relevant.
Actinium-225 DOTA-LM3 in 35 patients after standard PRRT
A retrospective review of 57 actinium-225 DOTA-LM3 cycles given from 2022 to 2024, alone or with lutetium-177 DOTA-LM3. Early effects were mostly mild, chiefly nausea. New grade 3 or 4 late effects included thrombocytopenia in 7, anaemia in 2, kidney and liver toxicity in 2 each and acute myeloid leukaemia in 1. Thirteen patients died during follow-up; the authors judged the treatment relatively safe with promising survival.
Making actinium-225 DOTA-LM3, and one patient
Labelling DOTA-LM3 with actinium-225 under validated conditions gave over 97% radiochemical purity and decay-corrected yields above 80%, with little free actinium released in serum over five days. One patient with pancreatic neuroendocrine cancer that had progressed after lutetium-177 therapy had a partial remission without clinically relevant blood, kidney or liver toxicity.
Case: esthesioneuroblastoma, actinium plus lutetium
A 45-year-old woman with recurrent metastatic esthesioneuroblastoma, a nasal-cavity cancer, received two cycles of combined actinium-225 and lutetium-177 DOTA-LM3 after lutetium-177 DOTATOC had failed. There were no acute side effects, imaging showed a partial response in most lesions, and her pain improved.
Case: no tumour left at autopsy after one alpha cycle
A 78-year-old man with a recurrent neuroendocrine tumour arising in a tailgut cyst received one cycle of actinium-225 DOTA-LM3. He died two months later of an unrelated stomach cancer, and autopsy found no remaining neuroendocrine tumour.
Case: parotid gland metastasis
A 38-year-old woman whose pancreatic neuroendocrine cancer had spread to the parotid gland and liver, and had progressed after DOTATOC therapy, reached partial remission at all sites after two cycles of combined actinium-225 and lutetium-177 DOTA-LM3.
Case: rapidly progressing pancreatic tumour
A 58-year-old woman with a pancreatic neuroendocrine tumour that had become grade 3 and progressed through several treatments, including lutetium-177 DOTATATE, received three cycles of combined lutetium-177 and actinium-225 DOTA-LM3. Bone and lymph node lesions regressed completely, liver disease improved, and she was able to return to full physical activity.
Case: actinium-225 DOTA-LM3 after standard alpha therapy
A 60-year-old woman with a grade 3 small-bowel neuroendocrine tumour had only stable disease after lutetium-177 and actinium-225 DOTATATE. Actinium-225 DOTA-LM3 alone was then followed by a favourable response on FDG PET, which the authors describe as the first direct comparison in one patient.
Case: liver metastases treated through the hepatic artery
A young patient with high-grade liver metastases from a pancreatic neuroendocrine tumour, which did not take up the agonist DOTATOC, received lutetium-177 DOTA-LM3 into the liver's artery. Molecular imaging showed near-complete remission and CT a partial remission, without significant toxicity.
Case: finding the source of ectopic Cushing syndrome
In a 53-year-old woman with Cushing syndrome whose source was hard to find, gallium-68 DOTA-LM3 PET showed a focus in the head of the pancreas. Surgery removed it and confirmed it as the cause.
Terbium-161 against lutetium-177 on DOTA-LM3 in mice
In cells, terbium-161 DOTA-LM3 was 102 times as potent as lutetium-177 DOTA-LM3, while terbium-161 improved the agonist DOTATOC only four- to five-fold. In tumour-bearing mice terbium-161 DOTA-LM3 delayed tumour growth more and prolonged survival. The authors link this to the antagonist staying on the cell membrane, where terbium's short-range electrons act.
Terbium-149 alpha therapy in mice
Labelled with the short-lived alpha emitter terbium-149, DOTA-LM3 was slightly more potent than DOTATATE on rat pancreatic tumour cells. In mice, one 5 MBq dose extended median survival to 19 days and two doses to 29 days, against 8 days untreated. Up to 40 MBq caused no relevant blood or kidney changes in mice without tumours.
Why terbium-161 adds dose: cell dosimetry
In CA20948 tumour cells, terbium-161 DOTA-LM3 delivered about 3.8 times the nuclear dose of its lutetium-177 form, mainly from internal conversion electrons rather than Auger electrons. Its survival curve had an extra quadratic term that the terbium-161 agonist lacked, which the authors suggest may reflect membrane damage.
Cell shape and dose-response modelling
Building realistic cell models from microscope images changed calculated cell doses by 11 to 22% compared with simple spheres, but the dose-response fits for lutetium-177 and terbium-161 DOTA-LM3 (linear-quadratic) and DOTATATE (linear) held either way.
Blood counts in mice after high activities
At 20 MBq per mouse, terbium-161 DOTA-LM3 was well tolerated. At 100 MBq, platelets fell by 30 to 50% and red cells by 6 to 12% at day 10 with the antagonist, more than with DOTATATE; all counts were normal by day 56 and organ changes were minimal. Organ doses were higher for the antagonist.
Receptor binding across species
On fresh-frozen brain sections from mice, rats, monkeys and people, lutetium-177 DOTA-LM3 bound SSTR2-rich regions specifically and saturably. Unlabelled DOTA-LM3 and its lutetium complex had similar affinity, but the gallium complex bound markedly less tightly.
Neodymium-140 as a PET generator in mice
Neodymium-140 DOTA-LM3 reached 13% of the injected dose per gram in the pancreas, which carries the receptor, at 16 hours in mice with lung tumour grafts. About 56% of the daughter radionuclide washed out of the pancreas before it decayed, because a non-internalising antagonist leaves it at the surface.
A critical appraisal of SSTR antagonists
Antagonist tracers give higher tumour-to-background ratios and find more liver lesions, and lutetium-177 DOTA-LM3 has promising uptake and dosimetry. The evidence, however, comes mostly from small, mixed early-phase studies; blood toxicity is higher and no prospective trial has shown a survival benefit.
Dosing Data
DOTA-LM3 has no approved label. It is dosed by radioactivity, not by weight of peptide, and is injected into a vein in a nuclear-medicine department. The rows below are the activities given in the published human studies carded above. The actinium-225 reports do not state activities in their abstracts, so they have no row.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no regulator's label that says in what form DOTA-LM3 is supplied. It is a radioactive drug: the next part says where it is prepared and given.
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: DOTA-LM3 is a radioactive drug, prepared and given in nuclear-medicine departments, and its dose is an amount of radioactivity (MBq or GBq), not a weight.
This page's dosing note: “DOTA-LM3 is labelled in a hospital radiopharmacy shortly before use and given by radioactivity in a nuclear-medicine department; no reconstitution maths applies to it.”
Source: this page's own note in Dosing Data below; the amount of each dose row in Dosing Data below.
Storage before and after mixing
Unknown: no label on file says how DOTA-LM3 is stored. It is a radioactive drug held by the nuclear-medicine department that prepares and gives it (see the part above); the home rules for a mixed vial in the mixing guide do not apply to it.
How it is taken
As it was given in human studies: Intravenous (Per cycle; Lutetium-177 DOTA-LM3, metastatic neuroendocrine neoplasms (51 patients)).
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Lutetium-177 DOTA-LM3, metastatic neuroendocrine neoplasms (51 patients): Cycles as given in the study; Terbium-161 DOTA-LM3, phase 0 dosimetry (8 patients): Imaging up to 168 hours; Gallium-68 DOTA-LM3 PET (8 patients): Imaging up to 2 hours.
When effects appear: unknown; no source on this page gives a time to effect for DOTA-LM3. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Imaging doses: grade 2 nausea in 2 of 8 patients and grade 1 vomiting in 1; effective dose about 0.025 mSv per MBq; Lutetium-177 therapy: grade 3 thrombocytopenia in 3 of 51 patients and mild nausea in 5; no kidney or liver decline reported; Actinium-225 therapy: mostly mild nausea early; later grade 3 or 4 low platelets, anaemia, low white cells, kidney and liver toxicity in some patients, and one acute myeloid leukaemia among 35; Kidneys, spleen and bone marrow receive more radiation than with agonists such as DOTATOC. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping DOTA-LM3. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the human studies above”).
Interactions
Unknown: a PubMed search for human interaction studies of DOTA-LM3 (reviewed 2026-10-28) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of DOTA-LM3 products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against DOTA-LM3's expected mass, 1,550.2 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: In Clinical Trials (Not approved: Drugs@FDA and the EMA medicines list hold no record (searched October 28, 2026)). Sport: Prohibited (S0 catch-all).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the human studies above.
Contraindications & Cautions
No approved label exists, so there are no official contraindications. Points from the studies:
Legal Status
DOTA-LM3 is investigational in every jurisdiction checked.
Frequently Asked Questions
?What is DOTA-LM3?
A synthetic cyclic peptide, LM3, that blocks somatostatin receptor 2, joined to a DOTA chelator that holds a radioactive metal for imaging or therapy.
?How is it different from DOTATATE?
DOTATATE activates the receptor and is taken into the cell. DOTA-LM3 blocks it and stays mostly on the surface, which in studies meant more binding to tumours but also more radiation to kidneys, spleen and bone marrow.
?What has it been used for?
Gallium-68 DOTA-LM3 PET scans of neuroendocrine tumours, and radioligand therapy with lutetium-177, terbium-161 or actinium-225, often in people whose disease progressed after standard treatment.
?What activity is given?
A median 6.1 GBq of lutetium-177 per cycle in the first treatment study, a 1 GBq test injection of terbium-161 in the phase 0 study, and about 172 MBq of gallium-68 for a scan.
?Is DOTA-LM3 approved?
No. It is investigational and is given only in nuclear-medicine departments within studies or specialist programmes.
References
- [other] PubChem CID 168355559, DOTA-LM3: formula C69H93ClN16O19S2, molecular weight 1550.2. Read October 28, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/168355559
- [clinical-trial] Baum RP, et al. "First-in-Humans Study of the SSTR Antagonist (177)Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy." J Nucl Med, 2021;62(11):1571-1581. PMID: 33674401.
- [clinical-trial] Zhu W, et al. "A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors." J Nucl Med, 2021;62(10):1398-1405. PMID: 33579804.
- [clinical-trial] Zhu W, et al. "A prospective randomized, double-blind study to evaluate the diagnostic efficacy of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with (68)Ga-DOTATATE." Eur J Nucl Med Mol Imaging, 2022;49(5):1613-1622. PMID: 34874478.
- [clinical-trial] Fricke JG, et al. "Targeted β(-)-Particle Plus Conversion and Auger-Electron Therapy with (161)Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study." J Nucl Med, 2026;67(3):416-422. PMID: 41381241.
- [clinical-trial] Perrone E, et al. "Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival." Cancers (Basel), 2025;17(18). PMID: 41008911.
- [pubmed] Greifenstein L, et al. "Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3." Pharmaceuticals (Basel), 2026;19(1). PMID: 41599769.
- [pubmed] Perrone E, et al. "Recurrent Metastatic Esthesioneuroblastoma: First-in-human α/β PRRT With Actinium-225/Lutetium-177-DOTA-LM3 SSTR Antagonist Achieving Partial Response After Failure of Lutetium-177-DOTATOC PRRT." Clin Nucl Med, 2026;51(10):e964-e967. PMID: 42545133.
- [pubmed] Perrone E, et al. "First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3." Clin Nucl Med, 2026;51(7):e484-e486. PMID: 41308086.
- [pubmed] Perrone E, et al. "TANDEM Peptide Receptor Radionuclide Therapy Using [ 225 Ac]Ac-/[ 177 Lu]Lu-DOTA-LM3 in a Patient With Parotid Gland Metastasis From Pancreatic Neuroendocrine Neoplasm." Clin Nucl Med, 2025;50(10):e605-e607. PMID: 40051072.
- [pubmed] Perrone E, et al. "Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with (177)Lu/(225)AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas." Diagnostics (Basel), 2024;14(9). PMID: 38732321.
- [pubmed] Speicher T, et al. "First Successful In-Human Application of 225Ac-DOTA-LM3 Mono-PRRT for the Treatment of an Otherwise Therapy-Resistant Neuroendocrine Tumor (NET G3)." Clin Nucl Med, 2025;50(1):101-102. PMID: 39626292.
- [pubmed] Zhang J, et al. "Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist." Clin Nucl Med, 2020;45(3):e165-e168. PMID: 31977464.
- [pubmed] Bastian MB, et al. "Ectopic Cushing Syndrome Localized by 68 Ga-DOTA-LM3 PET/CT." Clin Nucl Med, 2024;49(11):1031-1032. PMID: 39207826.
- [pubmed] Borgna F, et al. "Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms." Eur J Nucl Med Mol Imaging, 2022;49(4):1113-1126. PMID: 34625828.
- [pubmed] Mapanao AK, et al. "Preclinical investigation of [(149)Tb]Tb-DOTATATE and [(149)Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy." Eur J Nucl Med Mol Imaging, 2025;52(4):1383-1398. PMID: 39743617.
- [pubmed] Spoormans K, et al. "The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for (161)Tb Compared with (177)Lu with a Higher Dose Response for [(161)Tb]Tb-DOTA-LM3 Than for [(161)Tb]Tb-DOTATATE." J Nucl Med, 2024;65(10):1619-1625. PMID: 39209546.
- [pubmed] Spoormans K, et al. "Morphological versus spherical cellular geometry models: impact on dose-response of CA20948 cells to (177)Lu- and (161)Tb-labeled DOTA-TATE and DOTA-LM3." EJNMMI Phys, 2025;13(1):8. PMID: 41432893.
- [pubmed] Busslinger SD, et al. "Comparison of the tolerability of (161)Tb- and (177)Lu-labeled somatostatin analogues in the preclinical setting." Eur J Nucl Med Mol Imaging, 2024;51(13):4049-4061. PMID: 39046521.
- [pubmed] McCutcheon C, et al. "Cross-Species Quantitative Benchmarking of SSTR2 Radioligands in Fresh-Frozen Brain Sections: An Adaptable Framework for Radiopharmaceutical Development." Mol Imaging Biol, 2026. PMID: 42423881.
- [pubmed] Severin GW, et al. "Neodymium-140 DOTA-LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing Vector." Front Med (Lausanne), 2017;4:98. PMID: 28748183.
- [review] Jafari E, et al. "From Bench to Bedside: A Critical Appraisal of Somatostatin Receptor Antagonists in the Theranostic Management of Neuroendocrine Neoplasms." J Nucl Med, 2026. PMID: 42754346.
- [registry] ClinicalTrials.gov API v2, read October 28, 2026: NCT04318561 (phase 1/2, gallium-68 labelled LM3 PET/CT in neuroendocrine tumours, completed).
Sources & Citations
Studies were read from their PubMed records on October 29, 2026. Regulatory status comes from Drugs@FDA and the EMA medicines list (searched October 28, 2026) and trial listings from ClinicalTrials.gov. Formula and weight are PubChem's. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.